Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of EUR 47.50 million. The enterprise value is 53.77 million.

Market Cap	47.50M
Enterprise Value	53.77M

Important Dates

The last earnings date was Thursday, February 19, 2026.

Earnings Date	Feb 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	258.57M
Shares Outstanding	n/a
Shares Change (YoY)	+499.81%
Shares Change (QoQ)	+15.59%
Owned by Insiders (%)	0.70%
Owned by Institutions (%)	13.91%
Float	256.65M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.23
PB Ratio	-8.73
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.33
EV / Sales	8.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.63

Current Ratio	2.63
Quick Ratio	2.45
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-9.55

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-74.09%
Return on Invested Capital (ROIC)	-98.07%
Return on Capital Employed (ROCE)	-248.68%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	87,620
Profits Per Employee	-307,498
Employee Count	75
Asset Turnover	0.38
Inventory Turnover	0.39

Taxes

In the past 12 months, Oncopeptides AB has paid 130,750 in taxes.

Income Tax	130,750
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +39.87% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+39.87%
50-Day Moving Average	0.35
200-Day Moving Average	0.35
Relative Strength Index (RSI)	27.51
Average Volume (20 Days)	4,886

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of EUR 6.57 million and -23.06 million in losses. Loss per share was -0.02.

Revenue	6.57M
Gross Profit	6.35M
Operating Income	-20.76M
Pretax Income	-22.93M
Net Income	-23.06M
EBITDA	-20.53M
EBIT	-20.76M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 7.60 million in cash and 13.79 million in debt, with a net cash position of -6.19 million.

Cash & Cash Equivalents	7.60M
Total Debt	13.79M
Net Cash	-6.19M
Net Cash Per Share	n/a
Equity (Book Value)	-5.44M
Book Value Per Share	-0.02
Working Capital	6.71M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-20.00M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	96.55%
Operating Margin	-315.88%
Pretax Margin	-348.96%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-499.81%
Shareholder Yield	-499.81%
Earnings Yield	-48.55%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3